Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 13/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966603 | 1.00 | ABL1 (0.37) | ABL1PIM3GCKMTNR1AMTNR1B | |
| SCHEMBL964596 | 0.91 | ABL1 (0.35) | ABL1PIM3GCKMTNR1AMTNR1B | |
| SCHEMBL964595 | 0.91 | ABL1 (0.35) | ABL1PIM3GCKMTNR1AMTNR1B | |
| SCHEMBL962381 | 0.90 | PIM3 (0.41) | ABL1PIM3MTNR1AMTNR1BMCL1 | |
| SCHEMBL962382 | 0.90 | PIM3 (0.41) | ABL1PIM3MTNR1AMTNR1BMCL1 | |
| SCHEMBL963542 | 0.89 | MTNR1A (0.41) | MTNR1AMTNR1BMCL1 | |
| SCHEMBL963543 | 0.89 | MTNR1A (0.41) | MTNR1AMTNR1BMCL1 | |
| SCHEMBL963489 | 0.88 | MET (0.38) | MCL1 | |
| SCHEMBL963488 | 0.88 | MET (0.38) | MCL1 | |
| SCHEMBL966843 | 0.86 | MAPT (0.38) | ABL1MTNR1AMTNR1BMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | ABL1 4132/4885PIM3 3705/4885GCK 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.